Molecular Partners AG

OTCPK:MLLC.F Stock Report

Market Cap: US$159.1m

Molecular Partners Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MLLC.F?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,614,1394.32%
Public Companies1,739,1304.65%
Institutions4,349,22211.6%
General Public13,140,18835.1%
Hedge Funds16,556,47344.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 64.82% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
26.9%
BVF Partners L.P.
10,050,173US$42.8m0%1.33%
17.4%
Suvretta Capital Management, LLC
6,506,300US$27.7m0%0.81%
5.43%
UBS Asset Management AG
2,032,263US$8.6m0.73%no data
4.65%
Novartis AG
1,739,130US$7.4m0%no data
2.56%
GAM Holding AG
958,054US$4.1m0%0.05%
2%
Patrick Amstutz
747,809US$3.2m0%no data
1.91%
Michael Stumpp
715,770US$3.0m0%no data
1.13%
Union Bancaire Privée, UBP SA
424,230US$1.8m0%0.03%
0.58%
ZKB Asset Management
217,950US$927.1k0%no data
0.53%
Acatis Anlageberatung fur Investmentfonds GmbH
200,000US$850.8k0%0.05%
0.33%
Fourton Fund Management Co. Ltd
123,946US$527.2k0%0.15%
0.33%
Zürcher Kantonalbank
122,369US$520.5k0%no data
0.27%
BlackRock, Inc.
101,402US$431.3k8.2%no data
0.19%
BCV Asset Management
70,000US$297.8k0%0.01%
0.11%
Migrosbank Asset Management
41,529US$176.7k0%0.01%
0.09%
William A. Burns
33,521US$142.6k0%no data
0.077%
Pictet Asset Management Limited
28,881US$122.8k0%no data
0.077%
Alexander Zurcher
28,697US$122.1k0%no data
0.07%
Renate Gloggner
26,151US$111.2k0%no data
0.058%
Philippe Legenne
21,850US$92.9k0%no data
0.046%
Steven H. Holtzman
17,281US$73.5k0%no data
0.035%
LLB Asset Management AG
13,005US$55.3k0%no data
0.028%
State Street Global Advisors, Inc.
10,335US$44.0k0%no data
0.016%
Michael Vasconcelles
6,071US$25.8k0%no data
0.016%
Sandip Kapadia
6,071US$25.8k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/18 02:47
End of Day Share Price 2025/10/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecular Partners AG is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard VosserJ.P. Morgan
Wei ChangLeerink Partners LLC
Daina GrayboschLeerink Partners LLC